Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome

Transplantation

Volumn 68, Issue 9, 1999, Pages 1318-1324

  Ishikawa, Akira ^b   Flechner, Stuart M ^a   Goldfarb, David A ^b   Myles, Jonathan L ^b   Modlin, Charles S ^b   Boparai, Navdeep ^b   Papajcik, Doreen ^b   Mastroianni, Barbara ^b   Novick, Andrew C ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RISK FACTOR;

EID: 0033571518     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199911150-00017     Document Type: Article

References (29)

1. Tesi RJ, Henry ML, Elkhammas EA, Ferguson, RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant 1993; 7: 343.
2. Almond P, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
3. Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal allograft rejection in cyclosporine treated recipients. Transplantation 1996; 62: 1235.
4. Massy Z, Guijarro C, Wiederkehr M, et al. Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. Kidney Int. 1996; 49: 518.
5. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early vs. late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993: 55: 993.
6. Solez, K, Axelsen, RA, Benediktsson, H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
7. Racusen LC, Solez K, Colvin RB, et al The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
8. Gaber LW, Schroeder TJ, Moore LW, et al. The correlation of Banff scoring with reversibility of first and recurrent rejection episodes. Transplantation 1996; 61: 1711.
9. Gaber LW, Moore LW, Alloway RR, et al. Correlation between Banff classification, acute renal rejection scores and reversal of rejection. Kidney Int 1996; 49: 481.
10. Davis P, Rabinowitz, P. Methods of numerical statistics, 2nd ed. Orlando: Academic Press, 1984.
11. Kaplan EL, Meier, P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
12. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187.
13. Bailar JC, Mosteller F. Medical uses of statistics. Boston: New England Journal Medical Books, 1986.
14. Nashan B, Moore R, Amlot P, et al. Randomized trial of basiliximab vs. placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 2: 1193.
15. Vincenti F, Kirkman R, Light S, et al. for the Dacluzimab triple therapy study group. Interleukin-2 receptor blockade with dacluzimab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
16. Gaber AO, First R, Tesi RJ, et al. Results of the double blind, randomized, multicenter, phase III trial of Thymoglobulin vs. Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66: 29.
17. Sollinger, HW for the US Renal Transplant Mycophenolate Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
18. Kahan BD, Podbielski J, Napoli K, et al. Immunosuppressive effects and safety of a sirolimus cyclosporine combination regimenfor renal transplantation. Transplantation 1998; 66: 1040.
19. Matas AJ, Gillingham KJ, Payne WD, et al. The impact of an acute rejection episode on long-term renal allograft survival T 1/2. Transplantation 1994; 57: 857.
20. Pelletier RP, Cosio F, Henry ML, et al. Acute rejection following renal transplantation. Evidence that severity is the best predictor of subsequent graft survival. Clin Transplant 1998; 12: 543.
21. Soroft JM, Vartanian RK, Olson JL, et al. Histologic concordance of paired renal allograft biopsy cores. Transplantation 1995; 59: 724.
22. Schweitzer EJ, Drachenberg CB, Anderson L, et al. Significance of the Banff borderline biopsy. Am J Kidney Dis 1996; 28: 585.
23. Saad R, Gritsch HA, Shapiro R, et al. Clinical significance of renal allograft biopsies with "borderline changes," as defined in the Banff schema. Transplantation 1997; 64: 992.
24. Rush DN, Henry SF, Jeffrey JR, et al. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994; 57: 208.
25. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 2129.
26. Colvin RB, Cohen AH, Saiontz C, et al Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 1997; 8: 1930.
27. Yilmaz S, Yilmaz A, Hayry P. Chronic renal allograft rejection can be predicted by area under the serum creatinine versus time curve (AUC-Cr). Kidney Int 1995; 48: 251.
28. Schroeder TJ, Weiss MA, Smith, RD, et al. The efficacy of OKT3 in vascular rejection. Transplantation 1991; 51: 312.
29. Fairchild RL. Chemokines: mediators of T cell recruitment and effector function during allograft rejection. Graft 1998; 1: 91.